(NASDAQ: VKTX) Viking Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Viking Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast VKTX's revenue for 2026 to be $7,852,158,809, with the lowest VKTX revenue forecast at $7,852,158,809, and the highest VKTX revenue forecast at $7,852,158,809. On average, 2 Wall Street analysts forecast VKTX's revenue for 2027 to be $7,008,056,762, with the lowest VKTX revenue forecast at $6,631,225,491, and the highest VKTX revenue forecast at $7,384,888,033.
In 2028, VKTX is forecast to generate $30,228,098,231 in revenue, with the lowest revenue forecast at $5,918,763,167 and the highest revenue forecast at $55,298,732,952.